Unleash Immuno Oncolytics
Fenton
About Unleash Immuno Oncolytics
Unleash IO develops oncolytic immunotherapy products shown to be highly specific and efficacious in animal models and human tissue samples. Unleash IO’s leading product, UIO-512, is an oncolytic adenovirus that targets both malignant cells and tumor-associated stroma cells. UIO-512 is armed with GM-CSF, a potent immune-modulatory cytokine, triggering an immune response towards the tumor. UIO-512 lead indication is in ovarian cancer, follow on indications include other solid tumors such as glioblastoma, melanoma and pancreatic cancer. Promising pre-clinical results in animal models and fresh human samples of ovarian cancers as well as in melanoma were published in top ranked peer-reviewed publications. Unleash IO is raising $3.5 M to conduct a phase I/II clinical trial in ovarian cancer with oncolytic immunotherapy UIO-512.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $3.0M
- Last round: Series Unknown (Feb 2018)
- Website: unleash.bio
- Phone: 314-730-0050
Industries & Categories
Biotechnology, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/unleash-immuno-oncolytics-12109 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.